Cancer · Austria
Myeloproliferative neoplasms
How is it diagnosed today? A blood test counts your blood cells. NCI PDQ
What do you need help with?
- Join a trialStudies open to new patients in your country, and abroad if you want.10 open trials in Austria
- Offer tissue or dataGive a sample or your health data to research.
- Get supportPatient groups, money and work, help for family.
- Access and costGetting a treatment that is not on offer here, and who pays.
- Questions for your doctorReady lists to print or copy before your next visit.
- Don't pay for thisOffers with no proof in people, and what to check first.
Where treatment stands
Four steps, from proven to unproven.
Approved in Austria
Usual treatment: Venesection, low-dose aspirin, hydroxyurea. NCI PDQ
7 medicines are approved for this disease in Austria:
- Anagrelide (Anagrelide Viatris, Xagrid, Agrylin) – approved in 2004
- Fedratinib (Inrebic) – approved in 2021
- Imatinib (Glivec, Imatinib Accord, Imatinib Teva) – approved in 2001
- Momelotinib (Omjjara, Ojjaara) – approved in 2024
- Peginterferon alfa-2a (Pegasys) – approved in 2002
- Ropeginterferon alfa-2b (Besremi, BESREMi) – approved in 2019
- Ruxolitinib (Jakavi, Ruxolitinib Viatris, Jakafi) – approved in 2012
An EU approval is valid in Austria. We did not check the national approvals in Austria, so some medicines under “Approved elsewhere” may be approved here too. We did not check whether they are sold or paid for there. Checked in the regulators' own texts on 11 Nov 2026.
Approved elsewhere (5)
- Hydroxycarbamide (Hydrea) – approved for it in France
- Luspatercept (Reblozyl) – approved for it in the US
- Pacritinib (Vonjo) – approved for it in the US
- Pipobroman (Vercyte) – approved for it in France
- Rusfertide (Mimrylo) – approved for it in the US
Being tested in people
10 open trials in Austria, 189 worldwide. See the trials
- 81-mg aspirin once daily (Phase 3)
- 81-mg aspirin twice daily (Phase 3)
- ACE-536 (Phase 3)
- Anagrelide (Phase 3)
Only in the lab or in animals
Not counted yet for this disease.
No proof it works
Animal worm medicines (ivermectin, fenbendazole) for cancer: not approved, and not enough research in people to know if they help. American Cancer Society: What to Know About Ivermectin (21 May 2026) · American Cancer Society: What to Know About Fenbendazole (21 Oct 2025)
Join a trial
Studies that are taking new patients in Austria. The trial team decides who can join. Change the country at the top.
Phase 1: first tests in people · Phase 2: does it help? · Phase 3: compared with the usual treatment
1 open trial in Austria with these filters
Tests oral nuvisertib in people with myelofibrosis
NCT04176198 · ClinicalTrials.gov
- Graz – Medical University of Graz
Age 18 and over
Contact the trial team
Available abroad (61 trials)
Nearest region first. Travel and treatment abroad are often not paid for; ask your health insurer first.
Tests INCA036978 for safety in people with myeloproliferative neoplasms
NCT07441694 · ClinicalTrials.gov
Countries: Belgium, Germany, Spain and 8 more
- Liège, Belgium – Centre Hospitalier Universitaire (CHU) de Liege
- Roeselare, Belgium – AZ Delta
- Aachen, Germany – University Medical Center Rwth Aachen
Age 18 and over
Contact the trial teamTests LY5830966 in adults with myelofibrosis after a prior JAK2 inhibitor
NCT06343805 · ClinicalTrials.gov
Countries: Spain, France, United Kingdom and 2 more
- Barcelona, Spain – Hospital Clinic de Barcelona
- Madrid, Spain – Hospital General Universitario Gregorio Marañón
- Madrid, Spain – Hospital Universitario Ramón y Cajal
Age 18 and over
Contact the trial teamTests JNJ-88549968 in people with CALR-mutated myeloproliferative neoplasms
NCT06150157 · ClinicalTrials.gov
Countries: Germany, Spain, France and 7 more
- Aachen, Germany – Universitaetsklinikum der RWTH Aachen
- Berlin, Germany – Charité Campus Benjamin Franklin
- Essen, Germany – Med. Universitatsklinik Essen
Age 18 and over
Contact the trial teamPRT12396 for Polycythemia Vera and Myelofibrosis, Two Rare Blood Cancers
NCT07469891 · ClinicalTrials.gov
Countries: Spain, France, Italy and 2 more
- Barcelona, Spain – Hospital Clinic de Barcelona
- Madrid, Spain – Hospital Universitario 12 de Octubre
- Madrid, Spain – Hospital Universitario Ramón y Cajal
Age 18 and over
Contact the trial teamTests BGB-11417 alone or with azacitidine in myeloid blood cancers
NCT04771130 · ClinicalTrials.gov
Countries: Germany, Spain, France and 6 more
- Leipzig, Germany – Universitaet Leipzig
- Ulm, Germany – Universitaetsklinikum Ulm AoR
- Barcelona, Spain – Hospital de la Santa Creu i Sant Pau
Age 18 and over
Contact the trial teamTests roginolisib with ruxolitinib in myelofibrosis not responding to JAK inhibitors
2024-515252-20-00 · EU Clinical Trials Register
Countries: Spain, Italy
- Barcelona, Spain – Hospital Universitari Vall d'Hebron
- L'Hospitalet de Llobregat, Spain – Institut Catala D'oncologia
- Madrid, Spain – Hospital Universitario HM Sanchinarro
Age 18 and over
Contact the trial teamTests INCA035784 safety in adults with myeloproliferative neoplasms
NCT07008118 · ClinicalTrials.gov
Countries: Belgium, Germany, Italy and 2 more
- Brussels, Belgium – Cliniques universitaires Saint-Luc
- Ghent, Belgium – Universitair Ziekenhuis Gent
- Leuven, Belgium – Universitaire Ziekenhuizen Leuven
Age 18 and over
Contact the trial teamTests roginolisib with ruxolitinib in adults with myelofibrosis
NCT06887803 · ClinicalTrials.gov
Countries: Spain, United Kingdom, Italy
- Barcelona, Spain – Vall d'Hebron University Hospital
- Barcelona, Spain – Avigunda Gran via de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat
- Madrid, Spain – START Madrid - CIOCC
Age 18 and over
Contact the trial teamTasquinimod for myelofibrosis that stopped responding to JAK inhibitors
NCT06605586 · ClinicalTrials.gov
Countries: Germany, Netherlands
- Aachen, Germany – Universitaetsklinikum Aachen AöR
- Amsterdam, Netherlands – Stichting Amsterdam UMC
- Groningen, Netherlands – Universitair Medisch Centrum Groningen
Age 18 and over
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial teamTests TL-895 with ruxolitinib in adults with myelofibrosis
NCT05280509 · ClinicalTrials.gov
Countries: Germany, Spain, France and 3 more
- Düsseldorf, Germany – Marien Hospital Duesseldorf
- Halle, Germany – Klinik fur Innere Medizin IV - Hamatologie/Onkologie, Universitatsklinikum Hall
- Lleida, Spain – Hospital Universitari Arnau de Vilanova
Age 18 and over
The registry has not updated this record for a long time. Ask the team whether it is still open.
Contact the trial teamTests pacritinib in people with myelodysplastic syndromes
NCT06303193 · ClinicalTrials.gov
Countries: United States
- Bethesda, United States – National Institutes of Health Clinical Center
Ages 12 to 120
Contact the trial teamTests momelotinib safety during and after stem cell transplant in myelofibrosis
NCT07104799 · ClinicalTrials.gov
Countries: United States
- Boston, United States – Massachusetts General Hospital
Age 18 and over
Contact the trial teamOral JBI-802 tested in adults with thrombocytosis-related blood disorders
NCT07612280 · ClinicalTrials.gov
Countries: Australia
- Adelaide, Australia – Royal Adelaide Hospital
- Melbourne, Australia – St Vincent's Hospital Melbourne
- Melbourne, Australia – Monash Medical Centre
Age 18 and over
Contact the trial teamZE74-0282 for Polycythemia Vera and Myelofibrosis With the JAK2 V617F Mutation
NCT07529951 · ClinicalTrials.gov
Countries: Australia, Uzbekistan
- Nedlands, Australia – Linear Clinical Research Ltd
- Tashkent, Uzbekistan – Republican Specialized Hematology Scientific and Practical Medical Center
Age 18 and over
Contact the trial teamAxatilimab With or Without Azacitidine for Advanced Blood Cancers of the Bone Marrow
NCT06523556 · ClinicalTrials.gov
Countries: United States
- Columbus, United States – Ohio State University Comprehensive Cancer Center
- Portland, United States – Oregon Health Science University
Age 18 and over
Contact the trial teamImetelstat Maintenance After Stem Cell Transplant for High-Risk Blood Cancers
NCT07909733 · ClinicalTrials.gov
Countries: United States
- Madison, United States – University of Wisconsin - Madison
Ages 18 to 80
Contact the trial teamGecacitinib around stem cell transplant in people with myelofibrosis and related blood cancers
NCT07883382 · ClinicalTrials.gov
Countries: China
- Shanghai, China – No. 197, Ruijin Second Road, Shanghai
Age 18 and over
Contact the trial teamTests a drug after transplant in people with myelofibrosis
NCT05535764 · ClinicalTrials.gov
Countries: United States
- Salt Lake City, United States – Huntsman Cancer Institute at the University of Utah
Age 18 and over
Contact the trial teamDMR-001 alone or with ruxolitinib for CALR-mutant myeloproliferative neoplasms
NCT07849231 · ClinicalTrials.gov
Countries: Australia, United States
- Adelaide, Australia – hospital not given
- Brisbane, Australia – hospital not given
- Liverpool, Australia – hospital not given
Age 18 and over
Contact the trial teamTesting Nelfinavir for Anemia in People With Myelofibrosis
NCT07281781 · ClinicalTrials.gov
Countries: United States
- Orange, United States – Chao Family Comprehensive Cancer Center, University of California, Irvine
Age 18 and over
Contact the trial teamTests a CMV vaccine in stem cell transplant donors and recipients
NCT07020533 · ClinicalTrials.gov
Countries: United States
- Atlanta, United States – Northside Hospital
- Boston, United States – Brigham and Women's Hospital
- Duarte, United States – City of Hope Medical Center
Ages 18 to 75
Contact the trial teamTests DISC-0974 in adults with myelofibrosis or myelodysplastic syndrome and anemia
NCT05320198 · ClinicalTrials.gov
Countries: Australia, United States
- Nedlands, Australia – Linear Clinical Research
- Saint Albans, Australia – Western Health
- Sydney, Australia – St Vincent's Hospital
Age 18 and over
Contact the trial teamTests CK0804 added to ruxolitinib in myelofibrosis patients
NCT05423691 · ClinicalTrials.gov
Countries: United States
- Houston, United States – The University of Texas MD Anderson Cancer Center
- New York, United States – Columbia University
- Sacramento, United States – UC Davis Health
Age 18 and over
Contact the trial teamTests CER-1236 cell therapy in adults with relapsed or hard-to-treat acute myeloid leukemia
NCT06834282 · ClinicalTrials.gov
Countries: United States
- Denver, United States – Colorado Blood Cancer Institute
- Houston, United States – The University of Texas MD Anderson Cancer Center
- Nashville, United States – Sarah Cannon Research Insitute
Ages 18 to 85
Contact the trial teamPMD-026 for Myelofibrosis and Related Myeloid Blood Cancers
NCT07379125 · ClinicalTrials.gov
Countries: United States
- St Louis, United States – Washington University School of Medicine
Age 18 and over
Contact the trial teamTests pacritinib with venetoclax and azacitidine in advanced myeloproliferative neoplasms
NCT07679334 · ClinicalTrials.gov
Countries: United States
- Buffalo, United States – Roswell Park Comprehensive Cancer Center
Age 18 and over
Contact the trial teamAdding ropeginterferon alfa-2b to ruxolitinib treatment in people with myelofibrosis
NCT07521046 · ClinicalTrials.gov
Countries: United States
- Salt Lake City, United States – Huntsman Cancer Institute at University of Utah
Age 18 and over
Contact the trial teamTests axatilimab with ruxolitinib in adults with myelofibrosis and chronic myelomonocytic leukemia
NCT07128381 · ClinicalTrials.gov
Countries: United States
- Houston, United States – The University of Texas M. D. Anderson Cancer Center
Age 18 and over
Contact the trial teamTests azacitidine, venetoclax and gilteritinib for FLT3-mutated leukemia that has returned or not responded
NCT04140487 · ClinicalTrials.gov
Countries: United States
- Houston, United States – M D Anderson Cancer Center
Age 18 and over
Contact the trial teamTests daratumumab to lower donor antibodies before stem cell transplant
NCT06398457 · ClinicalTrials.gov
Countries: United States
- Baltimore, United States – Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Age 18 and over
Contact the trial teamTests edetate calcium disodium or succimer with chemotherapy in leukemia or myelodysplastic syndrome
NCT03630991 · ClinicalTrials.gov
Countries: United States
- Houston, United States – M D Anderson Cancer Center
Age 1 and over
Contact the trial teamIvosidenib and venetoclax, with or without azacitidine, for IDH1-mutated blood cancers
NCT03471260 · ClinicalTrials.gov
Countries: United States
- Boston, United States – Dana-Farber Cancer Institute
- Cleveland, United States – Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
- Houston, United States – M D Anderson Cancer Center
Age 18 and over
Contact the trial teamTests ruxolitinib with abemaciclib in adults with myelofibrosis
NCT05714072 · ClinicalTrials.gov
Countries: United States
- Basking Ridge, United States – Memorial Sloan Kettering Basking Ridge
- Commack, United States – Memorial Sloan Kettering Suffolk - Commack
- East White Plains, United States – Memorial Sloan Kettering Westchester
Age 18 and over
Contact the trial teamWJ01024 alone or with ruxolitinib in people with myelofibrosis
NCT07802405 · ClinicalTrials.gov
Countries: China
- Zhengzhou, China – Henan Cancer Hospital
Age 0 and over
Contact the trial teamTests ivosidenib with ruxolitinib in advanced blood cancers with an IDH1 gene change
NCT06291987 · ClinicalTrials.gov
Countries: United States
- Chicago, United States – University of Chicago Medicine-Comprehensive Cancer Center
- Milwaukee, United States – Froedtert Hospital & the Medical College of Wisconsin
Age 18 and over
Contact the trial teamTests BEBT-507 injection in adults with polycythemia vera
NCT07012109 · ClinicalTrials.gov
Countries: China
- Tianjin, China – Blood Diseases Hospital Chinese Academy of Medical Sciences
Ages 18 to 75
Contact the trial teamThiotepa-Based Chemotherapy Before Donor Stem Cell Transplant for Blood Cancers
NCT07565220 · ClinicalTrials.gov
Countries: United States
- Pittsburgh, United States – UMPC Hillman Cancer Center
Age 18 and over
Contact the trial teamStopping tacrolimus early after stem cell transplant in adults with blood cancers
NCT07302776 · ClinicalTrials.gov
Countries: United States
- Palo Alto, United States – Stanford University
Ages 18 to 80
Contact the trial teamRevumenib alone or with a JAK inhibitor for myelofibrosis
NCT07734077 · ClinicalTrials.gov
Countries: United States
- New York, United States – Icahn School of Medicine at the Mount Sinai Hospital
Age 18 and over
Contact the trial teamTests ruxolitinib with ulixertinib in people with myelofibrosis
NCT06773195 · ClinicalTrials.gov
Countries: United States
- Basking Ridge, United States – Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
- Boston, United States – Massachusetts General Hospital (Data Collection Only)
- Cleveland, United States – Cleveland Clinic
Age 18 and over
Contact the trial team
Showing 40 of 61. Use the filters to narrow the list.
How to get into an early trial
- A lab does not treat patients, so you cannot phone the lab to get a new treatment.
- Ask your doctor to look at phase 1 trials with you. These are the first tests in people.
- If one fits, your doctor sends a referral to the trial centre.
- The trial team checks whether you can join and decides.
Trial data: ClinicalTrials.gov, courtesy of the U.S. National Library of Medicine; it does not endorse this site. EU trials: EU Clinical Trials Information System (CTIS), European Medicines Agency. We show the registry records; the trial team has the last word on who can join.
Latest research
The five newest articles. The label comes from the PubMed index: whether it was tested in people, in animals or only in the lab.
- CAR-T Targeting of Mutant Calreticulin Selectively Eradicates Myeloproliferative Neoplasm-Sustaining Stem Cells.Blood · 2026-11-12
- In peopleHow I diagnose myeloid or lymphoid neoplasms with tyrosine kinase gene fusions.Am J Clin Pathol · 2026-11-04
- Low dose pre-transplant splenic radiotherapy for myeloproliferative neoplasms.Leuk Lymphoma · 2026-11-11
- Transfusion-related cost and time burden offsets associated with pacritinib versus best available therapy in patients with myelofibrosis: an economic evaluation based on the PERSIST-2 trial.Future Oncol · 2026-11-11
- The new Iron Age in polycythemia vera.Blood · 2026-11-12
Is it true?
Saw something on social media? Fact-check it now.
Get screened
For family members and people at higher risk: free checks can find some cancers early, before there are symptoms.
There is no routine screening for this cancer. If you have symptoms or a family history, talk to your doctor.
If several people in your family had cancer, ask your GP whether genetic counselling makes sense for you.
Offer tissue or data
You can help research move faster.
Give tissue or blood to research
Before an operation or a blood test, ask if left-over tissue or blood can go to a biobank.
- Does this hospital have a biobank?
- What will the sample be used for, and for how long?
- Can I change my mind later?
Share your health data
Ask your doctor whether there is a patient registry for your illness. You choose what you share.
Take part as a healthy volunteer
Some studies need people without the illness, often family members.
Volunteer studiesGet support
Patient groups in Austria
- Österreichische Krebshilfe
Free, anonymous counselling at regional centres in every federal state, psycho-oncology and emergency financial aid.
Phone: 01 7966450
- MPN Austria
Austrian patient association for people with myeloproliferative neoplasms (MPN) and their relatives. Member of MPNAN.
Help for every illness in Austria (4)
- 1450 – Rund-um-die-Uhr-Gesundheitsberatung
Austria's nationwide 24/7 telephone health advice line: trained staff assess symptoms and guide callers to the appropriate care.
- Telefonseelsorge Österreich – Notruf 142
Free, confidential 24/7 emotional support and crisis line for anyone in Austria, reachable on 142.
- Gesundheitsportal Österreich (gesundheit.gv.at)
Austria's official public health portal, offering quality-assured information on diseases, prevention, health services and patient rights.
- ARGE Selbsthilfe Österreich
ARGE Selbsthilfe Österreich represents the interests of self-help groups and patient organisations in Austrian social and health policy.
Available abroad: international groups (8)
- MPN Advocacy & Education International
Nonprofit providing education and advocacy for people living with myeloproliferative neoplasms.
- MPN Research Foundation
Foundation funding research into myeloproliferative neoplasms and supporting the MPN patient community.
- European Cancer Patient Coalition (ECPC)
Umbrella of European cancer patient groups, with a patient toolbox and a legal network for cancer patients.
- EURORDIS – Rare Diseases Europe
Alliance of over 1,000 rare disease patient organisations, with a list of rare disease helplines by country.
- MPN Advocates Network
Global network of MPN patient groups: advocacy education, MPN Awareness Day, global patient survey, webinars, MPN Horizons conference.
- Workgroup of European Cancer Patient Advocacy Networks
Network of pan-European cancer patient umbrella groups (including the blood cancer networks): joint advocacy, WECAN Academy training for patient advocates, patient experience data courses.
- European Patients' Forum (EPF)
Umbrella of European patient organisations and national patient coalitions.
- International Alliance of Patients' Organizations
Global alliance of patient organisations of all diseases, promoting patient-centred healthcare.
Money and work
If the illness stops you working, ask the hospital social worker which benefits you can claim.
- Which sick-pay or disability benefits can I apply for?
- Is there help for the carer in the family?
- Are travel costs to treatment paid back?
After a loss
If someone you love has died, you do not have to go through it alone. Many families ask themselves whether they missed something; the care team can talk this through with you.
We have no grief support group in Austria in our list yet. The hospital's social worker or palliative team can tell you where to find one.
Hospitals and hospices have chaplains and counsellors, for any faith or none.
Some families decide to give tissue to research after death, so that the illness can be studied. If you want to, ask the treating hospital early whether it has such a programme.
Access and cost
- If no trial fits, your doctor can ask the company and the medicines authority whether early access (compassionate use) is possible.
- In Austria the medicines agency BASG lists the early-access programmes that are running. BASG (Austria): list of compassionate use programmes, no. 054
- In the EU you may get planned care in another EU country. Ask your health insurer before you go. Your Europe: planned medical treatment abroad
- Some medicines for this disease are approved abroad but maybe not here: see “Approved elsewhere” under “Approved in Austria” above.
Don't pay for this
No one will cure you through a Facebook message or ask you to invest money.
- Animal worm medicines bought online (ivermectin, fenbendazole)
They are made for animals and not tested for cancer in people. High doses can cause seizures or coma, fenbendazole has caused liver damage, they may weaken your cancer treatment, and they can keep you out of a trial.
American Cancer Society: What to Know About Ivermectin (21 May 2026) · American Cancer Society: What to Know About Fenbendazole (21 Oct 2025) · ASCO: Oncologists urged to discuss ivermectin and fenbendazole (17 Jun 2026)
- “Treatment plans” offered in comments
Ask which published study in people is behind it. Usually there is none.
- Anyone who answers your post with a private treatment
Real trials are listed in a public registry. Check the number on ClinicalTrials.gov or the EU trial register.
- Strangers offering investments or “funds” for treatment
Do not reply and do not send money. Report the comment or message.
Before you pay for anything, ask three things
- Can I have a written price, with everything that is included?
- Which published study in people shows it helps my disease?
- What does my doctor say about it?
Questions for your doctor
Ready lists for a new diagnosis, during treatment, before a trial and before you pay. Open the question lists
Not medical advice. We show what is open and what is known; your care team decides what fits you.